New study to track Real-World impact of targeted radiation therapy for advanced prostate cancer
NCT ID NCT07290270
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 20 times
Summary
This study is observing men with metastatic prostate cancer who are receiving a drug called lutetium-177 vipivotide tetraxetan, a type of targeted radiation therapy. Researchers will track how well the treatment works in everyday medical practice, including changes in PSA levels, quality of life, and how long the cancer stays under control. The goal is to understand the real-world benefits and patterns of use for this therapy in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGShanghai, Shanghai Municipality, China, China
Conditions
Explore the condition pages connected to this study.